Evidence mapPaperPMID 33477364Full record

ReviewBiomedicines2021

Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.

Carlos M González-Casimiro, Beatriz Merino, Elena Casanueva-Álvarez, Tamara Postigo-Casado, Patricia Cámara-Torres, Cristina M Fernández-Díaz, Malcolm A Leissring, Irene Cózar-Castellano, Germán Perdomo

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Carlos M González-CasimiroInstituto de Biología y Genética Molecular, University of Valladolid-CSIC, 47003 Valladolid, Spain.ORCID 0000-0003-1640-7457
Beatriz MerinoInstituto de Biología y Genética Molecular, University of Valladolid-CSIC, 47003 Valladolid, Spain.ORCID 0000-0002-4761-3977
Elena Casanueva-ÁlvarezInstituto de Biología y Genética Molecular, University of Valladolid-CSIC, 47003 Valladolid, Spain.
Tamara Postigo-CasadoInstituto de Biología y Genética Molecular, University of Valladolid-CSIC, 47003 Valladolid, Spain.
Patricia Cámara-TorresInstituto de Biología y Genética Molecular, University of Valladolid-CSIC, 47003 Valladolid, Spain.
Cristina M Fernández-DíazMolecular Oncology Group, IMDEA Food Institute, CEI UAM + CSIC, 28049 Madrid, Spain.ORCID 0000-0003-0539-7636
Malcolm A LeissringInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine (UCI MIND), Irvine, CA 92697, USA.ORCID 0000-0001-7185-4255
Irene Cózar-CastellanoInstituto de Biología y Genética Molecular, University of Valladolid-CSIC, 47003 Valladolid, Spain.ORCID 0000-0002-6065-5362
Germán PerdomoInstituto de Biología y Genética Molecular, University of Valladolid-CSIC, 47003 Valladolid, Spain.ORCID 0000-0002-2301-0012
Universidad de Valladolid · ESMadrid Institute for Advanced Studies · ESUniversity of California, Irvine · US

Funding

European Foundation for the Study of Diabetes European Diabetes Research Programme on New Targets for Type 2 Diabetes supported by MSD-2017Junta de Castilla y León ORDER EDU/556/2019Junta de Castilla y León ORDER EDU/574/2018La Caixa" Foundation LCF/PR/PR18/51130007Ministerio de Ciencia e Innovación PID2019-110496RB-C21Ministerio de Ciencia e Innovación PID2019-110496RB-C22Ministerio de Economía, Industria y Competitividad SAF2016-77871-C2-1-RMinisterio de Economía, Industria y Competitividad SAF2016-77871-C2-2-RNIGMS NIH HHS R01 GM115617NIH HHS GM115617
6 · The paper itself

Abstract

Insulin-degrading enzyme (IDE) is a highly conserved and ubiquitously expressed metalloprotease that degrades insulin and several other intermediate-size peptides. For many decades, IDE had been assumed to be involved primarily in hepatic insulin clearance, a key process that regulates availability of circulating insulin levels for peripheral tissues. Emerging evidence, however, suggests that IDE has several other important physiological functions relevant to glucose and insulin homeostasis, including the regulation of insulin secretion from pancreatic β-cells. Investigation of mice with tissue-specific genetic deletion of

Indexed as

glucose transportersinsulin-degrading enzymeinsulin receptorinsulin resistanceliverpancreas

Identifiers

PMID33477364
PMCPMC7830943
OpenAlexW3124483803

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.